Sumatriptan Succinate
ApprovedSmall molecule
GSKSumatriptan Succinate is a small molecule that works as a Serotonin 1b (5-Ht1b) Receptor Agonist; Serotonin 1d (5-Ht1d) Receptor Agonist.[2] It is being used across 8 indications, with its most advanced program in Approved.[1]
Sumatriptan Succinate is one of 155 small molecule programs targeting Migraine Without Aura. It is currently in Approved.
8
Indications
18
Total Trials
0
Active Trials
154
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
357 competitors in Migraine
#DrugCompanyPhaseTrials
1Sumatriptan Succinate
GSKApproved
Aimovig
AmgenPreclinical
Emgality
Eli LillyPreclinical
Vyepti
LundbeckPreclinical
Bayer Aspirin
BayerPreclinical
Savella
AbbViePreclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Adempas
BayerPreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
Nitrostat
VViatris Specialty LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Migraine6 trials
Headache2 trials
Is Theophylline More Effective Than Sumatriptan in the Treatment of Post-dural Puncture Headache
Completed·—·Phase 4·NCT04257851·60 enrolled
Fasting Conditions2 trials
Dysmenorrhea1 trial
5 more indications
MPA1 trial
Phase 11 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sumatriptan Succinate. EMBL-EBI & Wellcome Sanger Institute.
- [4]